Trial Profile
A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Alveolar soft part sarcoma
- Focus Therapeutic Use
- Acronyms CASPS
- 16 Oct 2019 Results presented in The Institute of Cancer Research media release.
- 31 May 2019 Results assessing safety of cediranib in alveolar soft-part sarcoma patients, published in the Lancet Oncology.
- 22 Jan 2019 Planned End Date changed from 29 Jul 2018 to 1 Jan 2020.